This presentation reviews long-term clinical outcomes following CyberKnife® stereotactic radiosurgery (SRS) for the treatment of nonfunctioning pituitary adenomas (NFPAs). It highlights key findings on tumor control rates, the incidence and timing of new-onset hypopituitarism, and other treatment-related complications, including visual disturbances. The results support CyberKnife SRS as a safe and effective modality for both primary and residual/recurrent NFPAs, emphasizing the importance of dose planning and patient selection.
Learning Objectives:
- Summarize long-term tumor control outcomes following CyberKnife radiosurgery in patients with nonfunctioning pituitary adenomas.
- Identify major risk factors associated with post-SRS hypopituitarism and visual complications.
- Evaluate clinical indications and criteria for selecting patients suitable for CyberKnife SRS treatment.
Furen Xiao, M.D., Ph.D.
Institute of Medical Device and Imaging, National Taiwan University, Department of Neurosurgery, National Taiwan University Hospital, Taipei, Taiwan
Furen Xiao, M.D., Ph.D., is a leading Neurosurgeon at National Taiwan University, with specialized training from Stanford and UCLA. He is also an Assistant Professor at the National Taiwan University Institute of Medical Device and Imaging. With over two decades of clinical and academic experience, Dr. Xiao is internationally recognized for his work in stereotactic radiosurgery, brain and spine tumors and advanced medical imaging. His groundbreaking research in AI-driven medical image analysis and clinical data mining has been widely published in top-tier journals.
Fatima Shaukat, MBBS, FCPS, CHPE
CyberKnife® & TomoTherapy® Centre, JPMC, Pakistan
Dr. Fatima Shaukat is a leading Consultant Radiation Oncologist at the CyberKnife & TomoTherapy Centre, JPMC, Pakistan. Dr. Shaukat is the visionary founder of TEFF – Tumor Board Establishment Forum (JSMU Chapter) and co-founder of the Global Virtual Oncology Network (GVON). With a passion for advancing cancer care and fostering global collaboration, she brings a wealth of clinical expertise and innovative leadership to the field of radiation therapy.